[Three Patients with Acute Myocardial Infarction Associated with Targeted Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case Report].
Sorafenib is a tyrosine kinase inhibitor (TKI) of the vascular endothelial growth factor receptor (VEGFR) used for advanced renal cell carcinoma. Treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal cell carcinoma. However, in spite of its therapeutic efficacy, sorafenib causes a wide range of adverse events. Cardiovascular adverse events have been observed when sorafenib was used with targeted agents. Although these adverse events like hypertension, reduced left ventricular ejection fraction, cardiac ischemia or infarction were manageable with standard medical therapies in most cases, some had a poor clinical outcome. We report three cases of acute myocardial infarction associated with sorafenib in patients with metastatic renal cell carcinoma.
The Department of Urology, Gifu University Hospital.
Kimiaki
K
Takagi
The Department of Urology, Gifu University Hospital.
Manabu
M
Takai
The Department of Urology, Gifu University Hospital.
Kei
K
Kawata
The Department of Urology, Gifu University Hospital.
Kengo
K
Horie
The Department of Urology, Gifu University Hospital.
Mina
M
Kikuchi
The Department of Urology, Gifu University Hospital.
Taku
T
Kato
The Department of Urology, Gifu University Hospital.
Kosuke
K
Mizutani
The Department of Urology, Gifu University Hospital.
Kensaku
K
Seike
The Department of Urology, Gifu University Hospital.
Tomohiro
T
Tsuchiya
The Department of Urology, Gifu University Hospital.
Mitsuru
M
Yasuda
The Department of Urology, Gifu University Hospital.
Shigeaki
S
Yokoi
The Department of Urology, Gifu University Hospital.
Masahiro
M
Nakano
The Department of Cardiovascular, Gifu University Hospital.
Hiroaki
H
Ushikoshi
The Department of Pathology, Gifu University Hospital.
Tatsuhiko
T
Miyazaki
The Department of Urology, Gifu University Hospital.
Takashi
T
Deguchi
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000009:adverse effects; D009203:Myocardial Infarction / Q000139:chemically induced*; D009536:Niacinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000008:administration & dosage* / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D000077157:Sorafenib
D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib